Madam Chair, I thank the member for his question.
To start off, I would like to point out that the manufacturers are dealing with new products and with production challenges, and that we can expect fluctuations in their production.
We certainly have experienced a bump in the road with the recent reduction in what we can hope to receive from Pfizer during a period of about four weeks.
Pfizer assured us that we are to receive four million doses by the end of March and they continue to assure us of that. Moderna assures us that they will provide two million doses by the end of March. As we get closer to that deadline, there is more and more pressure on all of us to provide the right quantities.
I want to assure Canadians that we are working extremely hard with the manufacturers and with all the stakeholders to have as efficient a rollout as possible. We are dependent on what the manufacturers are able to produce with a new technology and a new type of vaccine, with the global demand or global market that is putting pressures on everyone.
I remain committed to providing as clear a picture to Canadians and to this committee and other committees as possible with regard to what we can expect and when and to working very closely with all stakeholders.